Section Arrow
ACRV.NASDAQ
- Acrivon Therapeutics
Quotes are at least 15-min delayed:2026/05/06 16:45 EDT
After Hours
Last
 2.08
-0.01 (-0.48%)
Bid
2.08
Ask
2.1
High 2.1269 
Low 2.08 
Volume 974 
Regular Hours (Closed)
Last
 2.09
+0.01 (+0.48%)
Day High 
2.14 
Prev. Close
2.08 
1-M High
2.24 
Volume 
423.38K 
Bid
2.08
Ask
2.1
Day Low
2.04 
Open
2.11 
1-M Low
1.44 
Market Cap 
89.03M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 1.96 
20-SMA 1.81 
50-SMA 1.67 
52-W High 3.56 
52-W Low 1.05 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.02/-1.47
Enterprise Value
90.56M
Balance Sheet
Book Value Per Share
2.63
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ERNAErnexa Therapeutics Inc.6.04+2.05+51.38%0PE
After Hours 6.35 +0.31 +5.13%
MNKDMannKind Corp3.56+0.7+24.48%143PE
After Hours 3.2969 -0.2631 -7.39%
AVTXAvalo Therapeutics21.81+5.55+34.13%-- 
After Hours 21.6 -0.21 -0.96%
GERNGeron Corp1.58-0.07-4.24%-- 
After Hours 1.58 0 0.00%
IBRXImmunityBio8.38+0.8+10.55%-- 
After Hours 8.4 +0.02 +0.24%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response andcell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.